Ultragenyx Pharmaceutical (RARE) Stock: Charts & Financials

Ultragenyx Pharmaceutical Inc.(RARE)

Biotechnology · Novato, CA

$14.46-0.04 (-0.28%)

Delayed quote: Oct 6, 2026, 4:00 PM EDT

About Ultragenyx Pharmaceutical Inc.

Ultragenyx Pharmaceutical Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing innovative treatments for rare and ultra-rare genetic conditions. Its operations span North America, Europe, and other international markets. The company's portfolio of marketed biologic products addresses several serious diseases. This includes Crysvita (burosumab), an antibody that targets fibroblast growth factor 23, used to treat X-linked hypophosphatemia and tumor-induced osteomalacia. Mepsevii offers enzyme replacement therapy for both pediatric and adult patients suffering from Mucopolysaccharidosis VII. Dojolvi is available for individuals with long-chain fatty acid oxidation disorders, while Evkeeza (evinacumab) provides a treatment option for homozygous familial hypercholesterolemia. Ultragenyx also boasts a robust pipeline of investigational therapies. Notable candidates include DTX401, an adeno-associated virus 8 (AAV8) gene therapy for glycogen storage disease type Ia, and DTX301, another AAV8 gene therapy aimed at ornithine transcarbamylase deficiency. Other promising developments feature UX143, a human monoclonal antibody for osteogenesis imperfecta; GTX-102, an antisense oligonucleotide designed for Angelman syndrome; UX701, targeting Wilson disease; and UX053, in development for glycogen storage disease type III. To advance its research and development efforts, Ultragenyx Pharmaceutical Inc. maintains strategic collaboration and licensing agreements with numerous partners, such as Kyowa Kirin Co., Ltd., Saint Louis University, REGENXBIO Inc., Bayer Healthcare LLC, GeneTx, Mereo, University of Pennsylvania, Arcturus Therapeutics Holdings Inc., Solid Biosciences Inc., and Daiichi Sankyo Co., Ltd. The company was founded in 2010 and operates from its headquarters in Novato, California.

Novato, CA

1,371 employees

www.ultragenyx.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Emil D. Kakkis

View full financials

Quarterly Report	TTM	Quarter ended Jun 2026	Quarter ended Mar 2026	Quarter ended Dec 2025	Quarter ended Sep 2025	Quarter ended Jun 2025	Quarter ended Mar 2025	Quarter ended Dec 2024	Quarter ended Sep 2024
Revenue	716.93M	214.00M	136.00M	207.00M	159.93M	166.50M	139.29M	164.88M	139.49M
Cost of Goods Sold	120.99M	34.00M	30.00M	29.00M	27.99M	23.00M	28.66M	16.89M	21.02M
Gross Profit	595.94M	180.00M	106.00M	178.00M	131.94M	143.49M	110.63M	147.98M	118.47M
Gross Profit Margin	83.1%	84.1%	77.9%	86.0%	82.5%	86.2%	79.4%	89.8%	84.9%
Total Operating Expenses	1.12B	255.00M	275.00M	292.00M	302.83M	251.38M	253.57M	270.26M	250.46M
Research & Development	773.21M	167.00M	187.00M	203.00M	216.21M	164.74M	165.77M	187.77M	170.11M
Selling, General & Administrative	351.62M	88.00M	88.00M	89.00M	86.62M	86.65M	87.80M	82.50M	80.35M
Operating Income (EBIT)	-528.89M	-75.00M	-169.00M	-114.00M	-170.89M	-107.89M	-142.94M	-122.28M	-131.99M
Operating Margin	-73.8%	-35.0%	-124.3%	-55.1%	-106.9%	-64.8%	-102.6%	-74.2%	-94.6%
Income Before Tax (EBT)	-582.54M	-91.00M	-184.00M	-128.00M	-179.54M	-114.00M	-149.77M	-133.40M	-133.21M
Interest Income	23.38M	5.00M	6.00M	6.51M	5.86M	5.79M	6.83M	9.55M	10.73M
Interest Expense	76.15M	22.00M	21.00M	19.00M	14.15M	14.04M	14.34M	15.52M	15.71M
Other Income/Expense	-53.65M	-16.00M	-15.00M	-14.00M	-8.65M	-6.12M	-6.83M	-11.13M	-1.23M
Net Income	-586.41M	-92.00M	-185.00M	-129.00M	-180.41M	-114.95M	-151.08M	-133.38M	-133.52M
Income Tax Expense	3.87M	1.00M	1.00M	1.00M	873K	947K	1.31M	-19K	303K
Net Profit Margin	-81.8%	-43.0%	-136.0%	-62.3%	-112.8%	-69.0%	-108.5%	-80.9%	-95.7%
EBITDA	-495.50M	-67.00M	-161.00M	-105.22M	-162.28M	-99.27M	-133.95M	-113.20M	-123.23M
EBITDA Margin	-69.1%	-31.3%	-118.4%	-50.8%	-101.5%	-59.6%	-96.2%	-68.7%	-88.3%
Depreciation & Amortization	33.39M	8.00M	8.00M	8.79M	8.61M	8.62M	8.99M	9.08M	8.76M
EPS Basic	-5.84	-0.90	-1.84	-1.29	-1.81	-1.17	-1.57	-1.39	-1.40
EPS Diluted	-5.84	-0.90	-1.84	-1.29	-1.81	-1.17	-1.57	-1.39	-1.40
Weighted Average Basic Shares	101.90M	101.90M	100.60M	99.90M	99.77M	98.46M	96.29M	95.68M	95.49M
Weighted Average Diluted Shares	101.90M	101.90M	100.60M	99.90M	99.77M	98.46M	96.29M	95.68M	95.49M

Quarterly Report

TTM

Quarter ended Jun 2026

Quarter ended Mar 2026

Quarter ended Dec 2025

Quarter ended Sep 2025

Quarter ended Jun 2025

Quarter ended Mar 2025

Quarter ended Dec 2024

Quarter ended Sep 2024

Revenue

716.93M

214.00M

136.00M

207.00M

159.93M

166.50M

139.29M

164.88M

139.49M

Cost of Goods Sold

120.99M

34.00M

30.00M

29.00M

27.99M

23.00M

28.66M

16.89M

21.02M

Gross Profit

595.94M

180.00M

106.00M

178.00M

131.94M

143.49M

110.63M

147.98M

118.47M

Gross Profit Margin

83.1%

84.1%

77.9%

86.0%

82.5%

86.2%

79.4%

89.8%

84.9%

Total Operating Expenses

1.12B

255.00M

275.00M

292.00M

302.83M

251.38M

253.57M

270.26M

250.46M

Research & Development

773.21M

167.00M

187.00M

203.00M

216.21M

164.74M

165.77M

187.77M

170.11M

Selling, General & Administrative

351.62M

88.00M

89.00M

86.62M

86.65M

87.80M

82.50M

80.35M

Operating Income (EBIT)

-528.89M

-75.00M

-169.00M

-114.00M

-170.89M

-107.89M

-142.94M

-122.28M

-131.99M

Operating Margin

-73.8%

-35.0%

-124.3%

-55.1%

-106.9%

-64.8%

-102.6%

-74.2%

-94.6%

Income Before Tax (EBT)

-582.54M

-91.00M

-184.00M

-128.00M

-179.54M

-114.00M

-149.77M

-133.40M

-133.21M

Interest Income

23.38M

5.00M

6.00M

6.51M

5.86M

5.79M

6.83M

9.55M

10.73M

Interest Expense

76.15M

22.00M

21.00M

19.00M

14.15M

14.04M

14.34M

15.52M

15.71M

Other Income/Expense

-53.65M

-16.00M

-15.00M

-14.00M

-8.65M

-6.12M

-6.83M

-11.13M

-1.23M

Net Income

-586.41M

-92.00M

-185.00M

-129.00M

-180.41M

-114.95M

-151.08M

-133.38M

-133.52M

Income Tax Expense

3.87M

1.00M

873K

947K

1.31M

-19K

303K

Net Profit Margin

-81.8%

-43.0%

-136.0%

-62.3%

-112.8%

-69.0%

-108.5%

-80.9%

-95.7%

EBITDA

-495.50M

-67.00M

-161.00M

-105.22M

-162.28M

-99.27M

-133.95M

-113.20M

-123.23M

EBITDA Margin

-69.1%

-31.3%

-118.4%

-50.8%

-101.5%

-59.6%

-96.2%

-68.7%

-88.3%

Depreciation & Amortization

33.39M

8.00M

8.79M

8.61M

8.62M

8.99M

9.08M

8.76M

EPS Basic

-5.84

-0.90

-1.84

-1.29

-1.81

-1.17

-1.57

-1.39

-1.40

EPS Diluted

-5.84

-0.90

-1.84

-1.29

-1.81

-1.17

-1.57

-1.39

-1.40

Weighted Average Basic Shares

101.90M

100.60M

99.90M

99.77M

98.46M

96.29M

95.68M

95.49M

Weighted Average Diluted Shares

101.90M

100.60M

99.90M

99.77M

98.46M

96.29M

95.68M

95.49M

Annual Report	12/31/2025	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018
Revenue	673.00M	560.23M	434.25M	363.33M	351.41M	271.03M	103.71M	51.49M
Cost of Goods Sold	109.00M	76.73M	45.21M	28.32M	16.01M	6.13M	9.01M	1.15M
Gross Profit	564.00M	483.50M	389.04M	335.01M	335.40M	264.90M	94.71M	50.35M
Gross Profit Margin	83.8%	86.3%	89.6%	92.2%	95.4%	97.7%	91.3%	97.8%
Total Operating Expenses	1.10B	1.02B	958.25M	983.93M	717.13M	595.02M	518.88M	421.72M
Research & Development	750.00M	697.87M	648.45M	705.79M	497.15M	412.08M	357.36M	294.00M
Selling, General & Administrative	349.00M	321.61M	309.80M	278.14M	219.98M	182.93M	161.52M	127.72M
Operating Income (EBIT)	-535.00M	-535.97M	-569.21M	-648.92M	-381.74M	-330.12M	-424.17M	-371.37M
Operating Margin	-79.5%	-95.7%	-131.1%	-178.6%	-108.6%	-121.8%	-409.0%	-721.2%
Income Before Tax (EBT)	-571.00M	-567.59M	-608.46M	-701.73M	-452.98M	-185.36M	-399.44M	-197.10M
Interest Income	25.00M	36.51M	26.69M	11.07M	1.93M	7.04M	13.24M	9.54M
Interest Expense	62.00M	63.04M	66.00M	43.02M	29.42M	33.29M	1.14M	N/A
Other Income/Expense	-36.00M	-31.61M	-39.26M	-52.81M	-71.24M	144.76M	24.73M	174.28M
Net Income	-575.00M	-569.18M	-606.64M	-707.42M	-454.02M	-186.57M	-402.73M	-197.61M
Income Tax Expense	4.00M	1.60M	-1.82M	5.70M	1.04M	1.21M	3.28M	514K
Net Profit Margin	-85.4%	-101.6%	-139.7%	-194.7%	-129.2%	-68.8%	-388.3%	-383.7%
EBITDA	-500.00M	-500.43M	-543.20M	-630.70M	-368.50M	-317.86M	-415.63M	-351.83M
EBITDA Margin	-74.3%	-89.3%	-125.1%	-173.6%	-104.9%	-117.3%	-400.8%	-683.2%
Depreciation & Amortization	35.00M	35.54M	26.01M	18.22M	13.24M	12.26M	8.54M	19.54M
EPS Basic	-5.83	-6.29	-8.25	-10.12	-6.70	-3.07	-7.12	-3.97
EPS Diluted	-5.83	-6.29	-8.25	-10.12	-6.70	-3.07	-7.12	-3.97
Weighted Average Basic Shares	98.60M	90.54M	73.54M	69.91M	67.80M	60.85M	56.58M	49.78M
Weighted Average Diluted Shares	98.60M	90.54M	73.54M	69.91M	67.80M	60.85M	56.58M	49.78M

Annual Report

12/31/2025

12/31/2024

12/31/2023

12/31/2022

12/31/2021

12/31/2020

12/31/2019

12/31/2018

Revenue

673.00M

560.23M

434.25M

363.33M

351.41M

271.03M

103.71M

51.49M

Cost of Goods Sold

109.00M

76.73M

45.21M

28.32M

16.01M

6.13M

9.01M

1.15M

Gross Profit

564.00M

483.50M

389.04M

335.01M

335.40M

264.90M

94.71M

50.35M

Gross Profit Margin

83.8%

86.3%

89.6%

92.2%

95.4%

97.7%

91.3%

97.8%

Total Operating Expenses

1.10B

1.02B

958.25M

983.93M

717.13M

595.02M

518.88M

421.72M

Research & Development

750.00M

697.87M

648.45M

705.79M

497.15M

412.08M

357.36M

294.00M

Selling, General & Administrative

349.00M

321.61M

309.80M

278.14M

219.98M

182.93M

161.52M

127.72M

Operating Income (EBIT)

-535.00M

-535.97M

-569.21M

-648.92M

-381.74M

-330.12M

-424.17M

-371.37M

Operating Margin

-79.5%

-95.7%

-131.1%

-178.6%

-108.6%

-121.8%

-409.0%

-721.2%

Income Before Tax (EBT)

-571.00M

-567.59M

-608.46M

-701.73M

-452.98M

-185.36M

-399.44M

-197.10M

Interest Income

25.00M

36.51M

26.69M

11.07M

1.93M

7.04M

13.24M

9.54M

Interest Expense

62.00M

63.04M

66.00M

43.02M

29.42M

33.29M

1.14M

N/A

Other Income/Expense

-36.00M

-31.61M

-39.26M

-52.81M

-71.24M

144.76M

24.73M

174.28M

Net Income

-575.00M

-569.18M

-606.64M

-707.42M

-454.02M

-186.57M

-402.73M

-197.61M

Income Tax Expense

4.00M

1.60M

-1.82M

5.70M

1.04M

1.21M

3.28M

514K

Net Profit Margin

-85.4%

-101.6%

-139.7%

-194.7%

-129.2%

-68.8%

-388.3%

-383.7%

EBITDA

-500.00M

-500.43M

-543.20M

-630.70M

-368.50M

-317.86M

-415.63M

-351.83M

EBITDA Margin

-74.3%

-89.3%

-125.1%

-173.6%

-104.9%

-117.3%

-400.8%

-683.2%

Depreciation & Amortization

35.00M

35.54M

26.01M

18.22M

13.24M

12.26M

8.54M

19.54M

EPS Basic

-5.83

-6.29

-8.25

-10.12

-6.70

-3.07

-7.12

-3.97

EPS Diluted

-5.83

-6.29

-8.25

-10.12

-6.70

-3.07

-7.12

-3.97

Weighted Average Basic Shares

98.60M

90.54M

73.54M

69.91M

67.80M

60.85M

56.58M

49.78M